INS and Hyperglycemia: Rapamycin has the potential to improve insulin signaling and reduce lipid accumulation in the liver induced by chronic low-grade systemic inflammation, but it also has a negative effect on β-cell function and hepatic gluconeogenesis, which may cause hyperglycemia.